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Abstract
Background: Asthma affects more than 5 million patients in the United Kingdom. Nearly 500,000 of these patients
have severe asthma with severe symptoms and frequent exacerbations that are inadequately controlled with
available treatments. The burden of severe asthma on the NHS is enormous, accounting for 80 % of the total
asthma cost (£1 billion), with frequent exacerbations and expensive medications generating much of this cost.
Of those patients with severe asthma, 70 % are sensitised to indoor aeroallergens, and the level of exposure to
allergens determines the symptoms; patients exposed to high levels are therefore most at risk of exacerbations and
hospital admissions.
The LASER trial aims to assess whether a new treatment, temperature controlled laminar airflow (TLA) delivered
by the Airsonett™ device, can reduce the frequency of exacerbations in patients with severe allergic asthma by
reducing exposure to aeroallergens overnight.
Methods: This multicentre study is a placebo-controlled, blinded, randomised controlled, parallel group trial. A total
of 222 patients with a new or current diagnosis of severe allergic asthma will be assigned with a random element
in a 1:1 ratio to receive either an active device for one year or a placebo device. The primary outcome is the
frequency of severe asthma exacerbations occurring over a 12-month period, defined in accordance with the
American Thoracic Society/European Respiratory Society (ATS/ERS) guidelines. Secondary outcomes include
changes in asthma control, lung function, asthma-specific and global quality of life for participants and their carers,
adherence to intervention, healthcare resource use and costs, and cost-effectiveness. Qualitative interviews will be
conducted to elicit participant’s and their partner’s perceptions of the treatment.
Discussion: Effective measures of allergen avoidance have, to date, proved elusive. The LASER trial aims to address
this. The study will ascertain whether home-based nocturnal TLA usage over a 12-month period can reduce the
frequency of exacerbations and improve asthma control and quality of life as compared to placebo, whilst being
cost-effective and acceptable to adults with poorly controlled, severe allergic asthma. The results of this study will
be widely applicable to the many patients with allergic asthma both in the UK and internationally.
Trial registration: Current controlled trials ISRCTN46346208 (Date assigned 22 January 2014).
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Background
Asthma affects over 5.4 million people in the United
Kingdom, with nearly 500,000 experiencing severe symp-
toms and frequent exacerbations that are inadequately con-
trolled with available treatments [1, 2]. The burden of severe
asthma on the National Health Service (NHS) is enormous,
accounting for 80 % of the total asthma cost (£1 billion;
https://www.asthma.org.uk/about/media/facts-and-statistics/)
with frequent exacerbations and expensive medications
generating much of this cost [3].
Current treatments including oral corticosteroids,
‘steroid-sparing’ immuno suppressants and monoclonal
antibody therapies are often of limited efficacy and have
potentially serious side effects (steroids, immunosuppres-
sive agents) or are prohibitively expensive (monoclonal
antibodies). The adverse effects of long-term oral steroids
include adrenal suppression, decreased bone mineral
density, diabetes, and increased cardiovascular mortality
[4]. The anti-IgE treatment Omalizumab™ has been shown
to reduce exacerbations by up to 50 % [5] and improve
the quality of life in severe allergic asthma but can cost as
much as £26,640 per year, [6], which is substantially more
than the current annual rental cost of a TLA device
(£2,088).
The 2011 British Thoracic Society (BTS) and Scottish
Intercollegiate Guidelines Network (SIGN) national asthma
guidelines [7] and 2010 WHO consultation on severe
asthma [8] have highlighted an urgent need for research in
severe asthma, acknowledging the limitations of available
treatments in severe asthma and the dearth of clinical trials
upon which to base management recommendations.
More than 70 % of severe asthmatic patients are sensi-
tised to common aeroallergens and/or moulds [9], and
the level of allergen exposure determines symptoms;
those exposed to high allergen levels are at an increased
risk of exacerbations and hospital admissions [10–13].
Allergen avoidance has been widely recognised as a
logical way of treating these patients [14]. In controlled
conditions, long-term allergen avoidance in sensitised
asthmatics reduces airway inflammation with consequent
symptomatic improvement, further supported by high-
altitude, clean-air studies [15–17].Unfortunately, effective
methods of allergen reduction have proved elusive [18, 19]
with current measures being unable to reduce allergen
load sufficiently to yield a consistent clinical improvement,
thus leaving a significant gap in the potential strategies for
reducing asthma severity through allergen reduction.
At night, airborne particles are carried by a persistent
convection current established by the warm body, trans-
porting allergens from the bedding area to the breathing
zone [20]. Proof-of-concept studies have shown the TLA
device reduces the total number of airborne particles and
significantly reduces the increase in particles generated
when turning in bed at night [21]. When compared to a
best-in-class traditional air cleaner, TLA is able to reduce
exposure to potential allergens by a further 99 % [22]. We
postulate that this highly significant reduction in noctur-
nal exposure, targeted to the breathing zone, explains why
TLA may succeed in an area where so many other mea-
sures, including air filters, have failed.
The TLA device, when compared to a placebo, has
proven efficacy on asthma-related quality of life and bron-
chial inflammation (measured by exhaled nitric oxide) in a
pan-European multicentre Phase III study, [23] (n = 282,
age range 7 to 70 years). The greatest benefit was seen in
the more severe asthma patients who required higher
intensity treatment and in patients with poorly controlled
asthma. Whilst not powered to ascertain an effect on
exacerbations, a post-hoc analysis showed a decreased
exacerbation rate in more severe patients treated with
TLA compared with placebo, with a trend towards signifi-
cance (mean 0.23 TLA; 0.57 placebo P = 0.07).
A further pragmatic, patient-centred RCT of this novel
non-pharmacological treatment in severe allergic asthma
is now warranted.
Methods
Study objectives
Primary aim
The primary aim of the trial is to determine whether
home-based nocturnal treatment with a temperature-
controlled laminar airflow (TLA) device can reduce the
frequency of severe asthma exacerbations over a 1-year
period. Exacerbations are defined according to the
American Thoracic Society (ATS) and European Respira-
tory Society (ERS) criteria, that is, an acute deterior-
ation in asthma that requires treatment with systemic
corticosteroids.
Secondary aims
The secondary aims include assessing the impact of
nocturnal TLA treatment on additional aspects of asthma
control including symptoms, reliever use, airway obstruc-
tion, and on the risk of future adverse asthma outcomes,
including an accelerated decline in lung function and the
side-effects of treatment over the 12-month period. The
impact of the treatment on the quality of life of the pa-
tients and their carers will be assessed using the Asthma
Quality of Life Questionnaire (AQLQ) and a generic
health-related quality of life questionnaire (EQ-5D-5L) for
trial participants and the Adult Carer Quality of Life ques-
tionnaire (ACQoL) for participant’s adult carers. The im-
pact of the treatment on both the NHS and social costs,
that is, healthcare utilisation, will be measured using pa-
tient questionnaires and a review of patient’s records and
education/work days lost, which will be assessed using the
Work Productivity Activity Impairment questionnaire
(WPAI) in both participants and their adult carers. These
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data will be further analysed to assess the cost-effectiveness
of the intervention, using a cost-utility analysis to deter-
mine the incremental cost per quality-adjusted life year
(QALY) gained. Finally, we aim to qualitatively evaluate the
perceptions, values and opinions of the participants and
their partners relating to the device to identify potential
modifications that may improve patient acceptance and
will inform future implementation of the device within
the NHS.
Exploratory aims
We will explore the possible associations of patient and
environmental factors that may be associated with a
treatment response.
Study design and setting
This is a multi-centre randomised, double-blind, placebo-
controlled parallel group trial comparing an active TLA
device with a placebo device over a 12-month period. The
device is installed in the participant’s home and each
participant is required to attend six study visits at their
usual referral hospital. Qualitative and health economics
methods have been incorporated to the trial. A summary
of the study design is illustrated in Fig. 1. The trial in-
cludes a 4-month internal pilot to assess the recruitment
and retention of participants, data collection methods and
quality, and participant and partner experience of the trial
through qualitative methods. Study recruitment com-
menced in May 2014. The plan is to conduct the trial in
as many as 15 centres in the UK.
Selection of participants
Recruitment and informed consent
As both new and prevalent severe asthma patients can
be included in the trial, a variety of approaches will be
used for recruitment. Some referral centres have cohorts
of well-characterised asthma patients with detailed clin-
ical and biological information, who can be contacted
directly by the research team and invited to local study
information events or a screening visit in the clinic.
Potential participants will also be identified through
existing clinic registers and referrals to severe asthma
clinics. Following advertisement and launch of the
website (http://www.lasertrial.co.uk/), a mechanism will
be in place for patients to self-refer to the study team
for screening. Participant’s adult carers and or their adult
partners will also be requested to attend events/visits
where possible because they will be recruited to partici-
pate in the trial. Participant information sheets will be
made available to potential participants prior to their
screening visit. Separate information sheets for Carers
and Partners will also be available. Participants invited
to the screening clinics will have been ‘pre-screened’
for known exclusion criteria such as age, smoking,
co-morbidities and concomitant use of excluded asthma
treatments. Informed consent for screening and trial pro-
cedures will be obtained from participants at Screening
Fig. 1 Study flow diagram
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Visit 1. Informed consent from partners and carers will
be obtained at either Screening Visit 1 or Randomisation
Visit 2.
Procedures performed at Screening Visit 1 include the
following:
1. Baseline pre-bronchodilator spirometry and bron-
chodilator reversibility testing.
2. Skin prick testing (SPT) to a panel of indoor
aeroallergens (dog, cat, house dust mite, and fungi).
3. Blood tests (peripheral blood eosinophil count and
total serum IgE in all cases and specific serum IgE
testing if the SPT is not available or cannot be
performed).
4. Asthma Control Questionnaire (ACQ) completion.
Participants will be provided with an electronic PEF
meter to measure morning and evening PEF (prior to
taking asthma medications) for 2 weeks prior to Ran-
domisation Visit 2. Participants will also complete an
asthma control diary for 2 weeks prior to Randomisa-
tion Visit 2.
Participants will be asked to return with this informa-
tion after 2 weeks, so their adherence and ability to per-
form daily readings can be assessed along with the
stability of their asthma prior to randomisation. Eligibil-
ity criteria will be confirmed at Randomisation Visit 2.
Patients who experience an exacerbation within the
2-week run-in period may be re-screened after a fur-
ther 2 weeks if they wish.
Inclusion criteria
To be included, participants must meet the following criteria:
1. Adult (aged 16–75 years inclusive)
2. A clinical diagnosis of asthma for ≥ 6 months
supported by evidence of any one of the following:
a. Airflow variability with a mean diurnal
peak expiratory flow (PEF) variability >15 %
during the baseline 2-week period or a
variability in FEV1 of > 20 % across clinic
visits within the preceding 12 months, with con-
comitant evidence of airflow obstruction (FEV1/
FVC ratio < 70 %).
b. Airway reversibility with an improvement in
FEV1 by ≥ 12 % or 200 ml after inhalation of
400 μg of salbutamol via a metered dose inhaler
and spacer at first study visit or within the
preceding 12 months.
c. Airway hyper-responsiveness demonstrated by
methacholine challenge testing with a provocative
concentration of methacholine required to cause
a 20 % reduction in FEV1 (PC20) of ≤8 mg/ml or
equivalent test.
3. Severe asthma (ATS/ERS guideline, 2013 [24])
defined as follows:
a. Requirement for high-dose inhaled corticosteroids
(ICS) (≥1000 μg/day beclomethasone (BDP) or
equivalent) plus a second controller (long-acting
ß2-agonist or anti-muscarinic, theophylline, or
leukotriene antagonist), and/or systemic
corticosteroids.
b. If on maintenance corticosteroids, the
maintenance dose must have been stable for
3 months; this excludes any interim need for
short-term steroid bursts to treat exacerbations.
4. Poorly controlled asthma demonstrated by BOTH
of the following:
a. Two or more severe asthma exacerbations,
requiring systemic corticosteroids ≥ 30 mg
prednisolone or equivalent daily (or ≥ 50 %
increase in dose if maintenance 30 mg
prednisolone or above), for 3 or more days,
during the previous 12 months, despite the use of
high-dose inhaled corticosteroids (ICS) and
additional controller medication.
b. ACQ (7-point) score > 1 at Screening Visit 1 and
Randomisation Visit 2.
5. Atopic status, defined as sensitisation to ≥ 1
perennial indoor aeroallergen (including house
dust mite, domestic pet or fungi) to which they
are likely to be exposed during the study,
demonstrated by a positive skin prick test
(wheal diameter ≥ 3 mm more than negative control)
or specific IgE ≥ 0.35 IU/L).
6. Exacerbation-free and taking stable maintenance
asthma medications (not including short-acting
bronchodilator or other reliever therapies) for at
least 2 weeks prior to Screening Visit 1.
7. Exacerbation free and taking stable maintenance
asthma medications (not including short-acting
bronchodilator or other reliever therapies) in the
period between Screening Visit 1 and Randomisation
Visit 2.
8. Able to use the TLA device during sleep on at least
5 nights per week (excluding holidays).
9. Able to give written informed consent prior to
participation in the trial and able to comply with the
trial requirements.
Exclusion criteria
1. Current smokers or ex-smokers abstinent
for < 6 months.
2. Ex-smokers with ≥ 15 pack/year smoking history.
3. Partner who is a current smoker and smokes
within the bedroom where the TLA device is
installed.
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4. TLA device cannot be safely installed within the
bedroom.
5. Intending to move out of study area to an area not
within reach of a participating referral hospital
within the follow-up period.
6. Documented poor treatment adherence.
7. Occupational asthma with continued exposure to
known sensitising agents in the workplace.
8. Previous bronchial thermoplasty within 12 months
of randomisation.
9. Treatment with Omalizumab (anti-IgE) within
120 days of randomisation.
10. Using long-term oxygen, continuous positive airway
pressure (CPAP) or non-invasive ventilation (NIV)
routinely overnight.
11. Uncontrolled symptomatic gastro-oesophageal
reflux that may act as a persistent asthma trigger.
12. Presence of clinically significant lung disease other
than asthma, including smoking-related chronic
obstructive pulmonary disease (COPD),
bronchiectasis associated with recurrent bacterial
infection, allergic broncho-pulmonary aspergillosis
(mycosis), pulmonary fibrosis, sleep apnoea,
pulmonary hypertension, or lung cancer, that in the
opinion of the Principal Investigator is likely to be
contributing significantly to the participant’s
symptoms.
13. Clinically significant co-morbidity
(including cardiovascular, endocrine, metabolic,
gastro-intestinal, hepatic, neurological, renal,
haematological and malignant conditions) that
remains uncontrolled with standard treatment.
14. Currently taking part in other interventional
respiratory clinical trials.
Randomisation and blinding
Participants will be assigned with a random element in a
1:1 ratio between the intervention and control groups using
a centralised randomisation system, Sealed Envelope™. A
nondeterministic minimisation algorithm will be used to
facilitate balanced allocation of participants across the two
treatment groups for 1) clinical site, 2) prevalent vs.
incident case and the following prognostic factors at base-
line: 3) exacerbation frequency in the previous 12 months
(2, 3, or ≥3), 4) use of oral corticosteroids (yes/no) and 5)
pre-bronchodilator FEV1 (>50 % predicted yes/no).
Sealed Envelope™ will have been provided with a list of
TLA product serial numbers by the manufacturing team
based in Sweden and will allocate a specific TLA prod-
uct to the participant. A secure e-mail notification will
be sent immediately to the local trial team to confirm
randomisation. A secure e-mail will be sent to the UK-
based engineering team. This will include the partici-
pant’s trial number, TLA product serial number, and an
exclusive, password protected, link for the engineering
team to log in and access the participant’s contact
details. The engineering team will then contact the par-
ticipant (within 72 hours of Randomisation Visit 2) to
arrange device delivery and installation without disclos-
ing the treatment allocation to the participant. All study
team members and the participants will be blind to
which device they have received.
Study intervention
The active TLA device (Airsonett™) significantly reduces
nocturnal allergen exposure by filtering ambient air
through a high efficiency particulate air filter, slightly
cooling (0.5-0.8° C) and ‘showering’ it over the parti-
cipant during sleep (Fig. 2). The reduced temperature
allows the filtered air to descend in a laminar stream,
displacing allergen-rich air from the breathing zone re-
ducing allergen exposure without creating draft or dehy-
dration. The device is installed next to the participant’s
bed by a qualified engineer from the company. The
device is pre-programmed to turn on and off at times
specified by the trial participant but can be turned on
and off by manual override if the participant wishes to
use the device for an extended period or turn the device
Fig. 2 The temperature-controlled Laminar Airflow (TLA) device (Airsonett.)
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off when not in use. The device is easy to use with no
identified safety concerns in previous trials. The device
is CE marked and licensed for use in the UK for allergic
asthma. The device uses the same amount of electricity
as a 60 W light bulb and has an anticipated life-span of
5 years with filter changes required every 6 months. Par-
ticipants will be asked to sleep under the device for at
least 5 nights per week except when on holiday during
the 12-month treatment period. Participants will record
whether they have used the device or not and number of
hours used on a daily basis, recorded in a ‘LASER’ diary.
Any additional hours used during the day will also be
recorded in the diary.
Control arm
The control treatment consists of a placebo device that
appears physically identical to the intervention device to
the study participant. These devices are adjusted to
deliver isothermal air, instead of slightly cooled air, and
holes in the filter effectively bypass it whilst still main-
taining an equivalent sound and airflow level to an active
device. This allows the placebo device to deliver a lam-
inar flow of non-filtered, non-descending, isothermal air
which, when mixed with the warm body convection, will
ascend towards the ceiling and thus have no effect on
the normal air flow pattern around the breathing zone.
No difference exists in the air delivery rate, perceived air
movements or sound level between an active or placebo
device. The human body is not able to detect an abso-
lute temperature difference of 0.75 °C, and as such, no
perceptible temperature difference exists when sleeping
beneath an active or a placebo device. Electricity usage is
the same as for active devices, and the filter is changed
at 6 month intervals.
Measurement of primary outcome
The primary outcome, severe asthma exacerbations, are
defined according to ATS/ERS guidelines [25] as a worsen-
ing of asthma requiring systemic corticosteroids ≥ 30 mg
prednisolone or equivalent daily (or ≥ 50 % increase in dose
if maintenance 30 mg prednisolone or above), for 3 or
more days. Courses of corticosteroids separated by ≥ 7 days
will be treated as separate severe exacerbations. Based on
this, an ‘exacerbation-dose’ of systemic corticosteroids is
defined as ≥ 30 mg prednisolone or equivalent daily if
not on a maintenance systemic corticosteroid treatment
or ≥ 50 % increase in dose if maintenance dose is 30 mg
prednisolone or above.
Participants will be asked to start an exacerbation diary
when starting an ‘exacerbation-dose’ of systemic corticoste-
roids (participant specific ‘exacerbation-dose’ is defined at
Randomisation Visit 2). The exacerbation diary will include
PEF measurements (using the trial electronic PEF device),
oral corticosteroid dose, reliever medication use, and
nocturnal asthma symptoms. Participants will be asked to
report severe exacerbations to their local site trial team as
soon as possible after onset via a dedicated telephone line
or a secure NHS e-mail account. Wherever possible, partic-
ipants will be asked to attend an exacerbation review with
their local trial team within 72 hours to corroborate the
exacerbation, at which the local trial team will complete the
case report form (CRF) using the exacerbation diary. The
definition of a severe asthma exacerbation with any one of
the following additional criteria must be met:
1. An associated decrease in morning PEF
compared to maximum morning PEF achieved
at baseline.
2. A 50 % increase in reliever medication on at least
2 of 3 successive days compared to baseline.
3. Increased nocturnal wakening.
If participants are not able to attend for an exacerba-
tion review, the exacerbation diary will be collected at
the next follow-up visit.
Measurement of secondary outcomes
Outcomes reflecting current asthma control will be mea-
sured in the clinic at 3, 6, 9 and 12 months, and will in-
clude (i) measures of lung function (pre-bronchodilator
FEV1, mean morning pre-bronchodilator peak expiratory
flow (PEF) rate over 2 weeks prior to the visit, fractional
concentration of exhaled nitric oxide (FENO)); (ii) mea-
sures of the risk of future adverse asthma outcomes
(severe exacerbations, systemic corticosteroid use over
the 12 months, post-bronchodilator FEV1 at 12 months);
(iii) symptom control patient-reported scores Asthma
Control Questionnaire (ACQ), Asthma Control Diary, and
Sino-Nasal Outcome Test (SNOT-22) score; and (iv)
health-related quality of life for both the study partici-
pant (standardised asthma quality of life questionnaire
(AQLQ(S)) and EuroQol 5-dimension 5-level question-
naire (EQ5D-5L) and the carer (Adult Carers Quality-of-
Life questionnaire (AC-QoL) at 12 months only). Re-
sponses to the EQ-5D will be converted into utilities using
UK population tariffs [26] and combined with survival in-
formation to generate quality-adjusted life years (QALYs).
A global evaluation of treatment effect (GETE score) will
be recorded at 12 months.
The usage of the device will be measured from partici-
pant reports at 3, 6, 9 and 12 months and also by an engin-
eer at the time of device filter change at 6 and 12 months.
We will assess the costs associated with the TLA
device (including acquisition, installation and servicing).
In addition, using patient questionnaires and review of
patients’ records, health and social care resource use
data will be collected. Resource use data will be valued
using NHS and social care costs schedules [27]. Work
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productivity and activity impairment (WPAI) question-
naires will be given to the participant (WPAI - Asthma)
at 3, 6, 9 and 12 months, and to the carer (WPAI – Care
Giver) if applicable at 12 months.
Thematic analysis of qualitative data will elicit infor-
mation on the participant and their partner’s perception
of the treatment device.
Exploratory analysis
Device adherence, objective markers of bronchial and
systemic allergy and inflammation, lung function mea-
sures, asthma and rhinitis control, quality of life and in-
door air quality assessments will be analysed to determine
factors that may be associated with treatment response.
Study visit schedule
The study visit schedule consists of two visits during the
screening period to assess eligibility and four visits dur-
ing the 12-month treatment period at 3-month intervals,
3, 6, 9 and 12 months post-randomisation (Table 1).
At the first visit (Screening Visit 1), after consent, the
following information is collected: participant’s demo-
graphics, past medical history, occupational history, par-
ticipant’s asthma history including exacerbation history
and a review of current asthma symptoms and current
medications, bronchodilator reversibility testing and al-
lergy testing (skin prick tests or serum specific IgE) are
performed, Blood samples are taken for total IgE and
peripheral blood eosinophil count. Participants are asked
to complete an ACQ and are issued with an electronic
peak expiratory flow meter for use during the trial.
At the second visit (Randomisation Visit 2), the asthma
control diary and peak flow diary is collected. Participants
complete the following questionnaires: ACQ, AQLQ, EQ-
5D-5L, WPAI-A, SNOT-22 and the LASER Indoor Air
Quality Questionnaire. Pre-bronchodilator spirometry is
performed, and FENO is measured. Allergy testing is
performed if this was not possible at Screening Visit 1.
Participants are issued with the following: (i) a LASER
diary for daily recording of overnight device use (hours,)
additional device use (hours,) time off work as a result of
asthma (hours) and dose of oral corticosteroids (mg);
(ii) exacerbation diary cards for completion at the onset of
an exacerbation throughout the trial (including PEF,
steroid dose, reliever medication use and nocturnal wak-
ening); and (iii) an Asthma Control Diary for completion
prior to their next follow-up visit (including morning pre-
bronchodilator PEF.) Participants will also be issued a
Resource Use Log and a participant identification card.
Participants whose partner and/or carer wish to partici-
pate in the trial are asked to attend together for either visit
1 or visit 2 so that Carer/Partner consent can be obtained.
Partners are asked to consent for participation in the
qualitative study and carers are asked to consent to
completion of questionnaires at visit 2 and at the 12-
month follow-up visit (ACQoL and WPAI-CG).
One month following the Randomisation Visit 2, par-
ticipants are contacted by telephone for their 1-month
telephone review, where device delivery and installation
will be confirmed, and any problems with the device or
trial can be addressed.
Follow-up visits are held at 3-, 6-, 9- and 12-months
post-randomisation. Participants collect 2 weeks of peak
flow recordings and an asthma control diary prior to each
follow-up visit. At the follow-up visits, participants com-
plete questionnaires (ACQ, AQLQ, EQ-5D-5L, SNOT-22
and WPAI-A) and perform pre-bronchodilator spirometry
and FENO. At each follow-up visit, exacerbation history is
reviewed along with self-reported device usage using the
LASER diary and healthcare resource use log. Device re-
ported use is also documented at each follow-up visit.
At the 12-month follow-up visit, a GETE questionnaire
will also be completed.
Participants will report severe exacerbations to their
local trial team throughout the trial, and if possible, face-
to-face reviews will be arranged to corroborate the diag-
nosis of a severe exacerbation. If a face-to-face review is
not possible, then a telephone review will be recorded.
Safety reporting
Participants will be asked about the occurrence of any
adverse events (AEs) (using the definition given in the
International Conference on Harmonisation - Good
Clinical Practice (ICH GCP) [28]) at each follow-up visit
and will be asked to report AEs to their local trial team
between visits. Only AEs that have a reasonable possibility
of being attributable to the device (that is an Adverse
Device Effect (ADE)) and any other AE considered to be of
clinical significance by the local principal investigator as
causing harm to the patient will be recorded. ADEs also
include any event resulting from insufficiencies or inad-
equacies in the instruction for use or deployment of the
device and includes any event that is a result of a user error.
Events exempt from recording are those related to
worsening asthma control or the main study outcomes,
namely the following:
1. An increase in rescue medication usage.
2. Additional courses of steroids for asthma
exacerbations.
3. Increased unscheduled healthcare usage including
GP and Emergency Department visits for
deteriorations in asthma control.
4. Time off work, College or University due to
worsening asthma control.
5. Hospitalisation due to asthma exacerbation.
6. Increased number or intensity of asthma
exacerbations.
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Table 1 Study visit schedule
iInformed Consent will be sought for the main trial and qualitative studies (during internal pilot and at completion of the follow-up period) at Screening Visit 1
iiPost Randomisation Telephone Review after 1 month (+/- 3 days) to review device usage and check device related technical issues have been addressed
iiiSevere Exacerbation Reporting. Participants will report severe exacerbations to their local trial team as soon as possible throughout the follow-up period
ivSerum Specific IgE only required if Skin Prick Tests not available
vPost-Trial Provision Period refers to treatment with an active TLA device free of charge including filters and technical support over a 4 year period
viAdult Carer / Partner participation in selected cases is entirely optional and will not influence participant’s eligibility for inclusion in the trial
viiInstallation within 10 working days of Randomisation
viiiDevice Exchange / Removal within 10 working days of last study visit or focus group involvement whichever comes last
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All serious adverse events (SAEs) and serious adverse
device effects (SADEs), defined as any untoward medical
occurrence seen in a patient that can be attributed
wholly or partly to the device and resulted in any of the
characteristics or lead to the characteristics of a Serious
Adverse Event) will be recorded on a serious adverse
event form and be reported within 24 hours to the
Oxford Respiratory Trials Unit (ORTU). A second med-
ical assessment of all reported SAE/SADEs will then be
performed, and if considered by either the PI or ORTU
to be possibly, probably or definitely related to the device
(SADE), will be expedited to the Sponsor, REC and device
manufacturer within 7 days of ORTU becoming aware of
the event, if fatal or life threatening, or otherwise within
15 days. Listings of adverse events will be provided to the
Data Safety Monitoring Committee (DSMC) and the
Sponsor when requested. The DSMC will report to the
TSC and Sponsor regarding the safety profile of the trial.
Statistics
The study will be reported in accordance with the Consol-
idated Standards of Reporting Trials statement and ICH
Guidelines for Good Clinical Practice. All study data will
be managed by ORTU using a bespoke database created
using OpenClinica Enterprise Edition software (OpenCli-
nica LLC, Waltham MA, USA). Confidentiality of partici-
pant data will be assured according to GCP.
Sample size
Based on an estimated rate of two severe asthma exacer-
bations per participant over the 12-month period in the
placebo group, a minimum of 222 participants (111 per
group) will be required to provide 80 % power (at 5 %
two-sided significance level) to detect a clinically mean-
ingful 25 % reduction in the average exacerbation rate in
the group using the TLA device.
This sample size is based on a Poisson regression
model, with the treatment group as the covariate and a
10 % overall dropout rate. A review of comparative
interventions of proven efficacy in severe asthma gave
effect sizes ranging from 21 to 63 %, with a mean of
41 %. Given that this is a pragmatic trial where we expect
our intervention to be less effective than an efficacy trial,
we have chosen a deliberately more conservative effect
size of 25 %. This represents on average, one less severe
exacerbation every 2 years.
Clinical outcomes analysis
The primary statistical analysis will be carried out on the
basis of intention-to-treat (ITT). The primary efficacy
endpoint in this study, the rate of clinically significant
exacerbations over the 12-month period, will be analysed
using a Poisson regression model to compare the rate of
asthma exacerbations between the two groups with log
of time used as an offset variable. Further analysis will
adjust for the baseline characteristics including the ACQ
score, age, body mass index (BMI) and sex.
Continuous secondary endpoints which involve repea-
ted measures at baseline, 3, 6, 9, and 12 months (including
measures of lung function, composite asthma control
scores and health-related quality-of-life measures) will be
analysed using longitudinal analysis methods, including
mixed effect models to determine any effect of the TLA
device over time. Continuous variables with only baseline
and 12 months data, (including lung function and carer
quality of life measures) will be analysed by analysis of co-
variance (ANCOVA) of the 12-month outcome adjusted
where appropriate for baseline, minimisation factors
and other important factors as detailed for the primary
outcome.
Kaplan–Meier curves and log-rank test will be used to
compare the time to first asthma exacerbation between
the two groups. Cox proportional hazards models will be
used to evaluate the effect of TLA device on the time to
first asthma exacerbation, adjusting for the same covari-
ates as in the primary analysis. Since the analysis of only
time to first exacerbation leaves out much of the data,
analysis incorporating multiple time-to-event (recurrent
exacerbations) methods will also be used, including the
Andersen–Gill extension.
The proportion of participants experiencing severe ex-
acerbations over the 12-month follow-up period will be
compared using a continuity-corrected Chi-squared test.
The duration of severe exacerbations, the total number
of days in an exacerbation state over the 12-month
follow-up period, and the number of health care utilisa-
tions will be compared between the two groups using
two-sample independent t-tests.
Exploratory sub-group analyses will include an assess-
ment of factors associated with an improved treatment
response including objective markers of bronchial and
systemic allergy and inflammation, lung function, asthma
and rhinitis control, quality of life and level of indoor air
quality. The predictive effect of the biomarkers on exacer-
bations will be assessed by including the biomarker as
an independent covariate together with the biomarker-
treatment interaction using Poisson regression modelling
in a multivariate framework (as described for the primary
outcome).
Missing data
We will attempt to minimize the missing data due to
item non-response during the long follow-up period by
ensuring timely contact with the participants and robust
follow-up procedures. The expected participant’s drop-
out has already been factored into the sample size calcu-
lation. Missing data will be reported with reasons given
where available, and the missing data pattern, explored.
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In order to be consistent with the ITT, missing data for
the primary endpoint will be imputed using multiple
imputation (MI) techniques. Our imputation model will
be sufficiently general to include all the baseline vari-
ables thought to be important predictors of the response
indicator of each target variable to be imputed. This will
improve the validity of the imputation model under the
missing at random (MAR) assumption on which the MI
is based. In addition, an ignorable likelihood-based ana-
lysis will be applied for the mixed effect models.
Interim analysis and criteria for early study termination
No interim analysis is planned; however, the DSMC will
perform regular reviews of all study outcome and ad-
verse event data to ensure that there is no difference in
rates of hospitalisation or exacerbation in either group.
The DSMC will determine final criteria for early study
termination, which may be based on clear-cut evidence
of worsened safety in one of the trial arms, and in the
case of evidence beyond reasonable doubt of clear-cut
benefit in the primary outcome measure, an effect
size which would change clinical practice in the pres-
ence of the current literature and understanding of the
disease area.
Economic evaluation
The perspective adopted in the economic evaluation will
be that of the National Health Service (NHS) and so-
cial services; therefore, productivity losses and over-the-
counter medication costs will not be included in the base
case analysis. However, in a sensitivity analysis, we will
assess the impact of including these costs on the cost-
effectiveness results.
A within-trial cost-utility analysis will explore the
incremental cost per QALY gained by TLA usage when
compared to sham-TLA usage. Cost and effect results
will be reported as means with standard deviations, with
mean differences between the two patient groups reported
alongside 95 % confidence intervals (CI). Incremental
cost-effectiveness will be calculated by dividing the dif-
ference in costs by the difference in effects. Uncertainty
around the incremental cost-effectiveness ratio (ICER) will
be explored using non-parametric bootstrapping [29].
Building on the results of the trial and subsequent
cost-effectiveness analysis, a Markov model will be con-
structed to determine the costs and outcomes, over the
life-time of the patient, of TLA usage. The model struc-
ture will be informed by results from this trial, and from
previously published studies, with experts within the
team advising on the final structure of the model. The
analysis will determine the cost per life year gained and
cost per QALY gained when nocturnal TLA treatment is
compared to placebo. The model will be run over the
patient lifetime, with costs and benefits discounted at a
rate of 3.5 %. Probabilistic sensitivity analyses will be
conducted to deal with uncertainty in model parameters
and cost-acceptability curves presented, [30] and will be
extended to consider the application of value of informa-
tion (VoI) techniques, which are included in economic
evaluations to inform policy decisions about the value of
further research.
Qualitative analysis
Informed consent for participation in the qualitative
study will be sought at Screening Visit 1. All partici-
pants taking part in the LASER trial will be invited to
take part in the qualitative study, although this is not
mandatory.
During the initial 4-month pilot phase of the trial, tele-
phone interviews will be conducted with participants.
Telephone interviews will follow a topic guide developed
in conjunction with the PPI members and will focus on
the study procedures to elicit aspects of the study that
may be improved. We will also gather information about
participant’s experience of using the TLA device. The
qualitative interviews will help to identify potential bar-
riers to recruitment, treatment adherence and device ac-
ceptability. Telephone interviews will be digitally recorded
and transcribed verbatim for analysis. Results of the tele-
phone interviews will be used to inform subsequent devel-
opment and refinement of trial processes. The interviews
will also be used to strengthen the frequently asked ques-
tions area of the website. Key themes identified during the
telephone interviews will be used to inform the topic
guide for the later focus group interviews.
Following completion of their 12-month treatment
period, participants who have consented to participation
in the focus group interviews will be invited to attend.
Focus groups will be held for both satisfied and non-
satisfied users. All interviews will be digitally recorded,
transcribed verbatim and entered into NVivo10, a quali-
tative software package for systematic and transparent
data management. Contributions by participants will re-
main anonymous. An identification using a pseudonym
will be assigned to each participant at recruitment. No
‘real’ names will be included in any reports. Care will be
taken to always ensure any direct quotes used in study
report or papers to illustrate the findings will not be
directly attributable to individuals.
We will use Framework Analysis, a three-stage analytic
process, to analyse the data. This involves identifying
initial themes by indexing the content of the data; this
then guides the formation of a framework within which
transcribed material is synthesised. Key categories are
then identified to help describe the data. Finally, patterns
of association are explored and attempts made to explain
why those patterns occur.
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Patient public involvement
Patient public involvement has been sought throughout.
PPI members have been engaged from the initial grant ap-
plication to trial design and delivery and continue to play
an active role in areas such as development of the trial
website. PPI members will continue to be involved as the
trial progresses, helping to guide the focus group interview
schedule and in the dissemination of the results.
Ethics
A favourable ethical approval for this study was granted
by the National Research Ethics Service (NRES) Commit-
tee, South Central – Berkshire (reference 14/SC/0092) on
26 February 2014. The trial will be conducted according
to the Declaration of Helsinki [31].
The main ethical issue in this trial is the provision of a
placebo device for a 1-year period. The trial team con-
sidered alternative ‘add-on’ treatments in severe asthma
(for example, omalizumab and bronchial thermoplasty),
but these vary greatly in indication, use and delivery; are
not suitable for every patient; and would therefore not
be able to be used consistently or safely in an ‘active’
control group. As the TLA device is unique in its design
and purpose and is intended as an addition to standard
asthma treatment, the use of a placebo device is war-
ranted here and was deemed acceptable by the service
users consulted on the study design.
Throughout the trial, participants in both treatment
arms will receive standard asthma care in accordance
with the national BTS/SIGN guidelines for the manage-
ment of asthma in adults. No treatments or care will be
withheld at any point in the study, with all participants
(in either arm) able to receive any care considered
appropriate by the treating physicians.
All participants completing at least 6 months of the
trial follow-up period will be offered the option of having
an active device in their home for a further 4 years, pro-
vided and maintained by the manufacturers Airsonett™.
Funding source, sponsor and trial oversight
This study has been funded through a competitive grant
application to the National Institute of Health Research
(NIHR) Health Technology Assessment (HTA) funding
stream. The sponsor for this trial is Portsmouth Hos-
pitals NHS Trust. The device is supplied to the sponsor
by the manufacturers Airsonett™. Under the terms of a
comprehensive supply agreement with the sponsor,
Airsonett™ will provide devices, installation and main-
tenance services and will install the devices directly into
the participant’s homes. In collaboration with the
sponsor, ORTU will oversee the quality assurance and trial
conduct with routine and for-cause audit performed in ac-
cordance Good Clinical Practice guidelines as appropriate.
A Trial Management Group (TMG) including the Chief
Investigator, Trial Coordinator, Trial Manager, Data Man-
ager and Trial Statistician are in contact weekly.
A Trial Steering Committee (TSC) will meet at least 6
monthly, and more frequently if required, to review the
trial progress and to ensure that it is being conducted in
accordance with the protocol, relevant regulations and
the principles of GCP.
A Data Safety and Monitoring Committee (DSMC)
will review trial progress and safety data. The DSMC is
independent of the trial investigators and will comprise
three independent members including two clinical spe-
cialists and a trial statistician.
Protocol amendments
Protocol amendments will be agreed upon with the Trial
Steering Committee, Data Safety and Monitoring Com-
mittee, Sponsor and Funding Body prior to submission
for ethical approval. Following ethical approval, protocol
modifications will be communicated with relevant par-
ties such as the trial investigators, the trial registry and,
if required, trial participants.
Dissemination policy
The results of the trial will be widely disseminated to
patients, health professionals, commissioners, policy
makers and the general public. Our patient public in-
volvement members will play a key role in this. The trial
results will be disseminated to a wide clinical audience
through publication in the HTA Journal series and an-
other high impact international peer‐reviewed scientific
journal. The respiratory community will be targeted
through presentations at international meetings of
respiratory disease (British Thoracic Society, European
Respiratory Society.) The commercial supplier, Airsonett,
has also agreed to support a symposium at a scientific
meeting to further disseminate the results.
Discussion
The LASER Trial will address an important research
question in severe allergic asthma.
To date, methods of allergen avoidance have lacked
the necessary evidence to support their widespread im-
plementation despite broncho-provocation experiments
demonstrating that aeroallergens can induce broncho-
spasm, eosinophilic airway inflammation, and increased
bronchial hyper-reactivity in sensitised patients.
A Cochrane review of house dust mite control mea-
sures in asthma concluded that chemical and physical
methods aimed at reducing exposure to house dust mite
allergens cannot be recommended. They recommended
that if further studies were to be considered that they
should be methodologically rigorous and use other
methods than those used so far.
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In designing the LASER Trial, we have attempted to
address the question of whether this novel allergen inter-
vention can reduce the frequency of severe exacerba-
tions and improve asthma control and quality of life as
compared to placebo, whilst being cost-effective and ac-
ceptable to adults with poorly controlled, severe allergic
asthma. Using a rigorous methodological approach and
with our primary outcome guided by our Patient Public
Involvement members, we hope that we will be able to
answer an important research question whilst keeping
outcomes relevant to patients, clinicians, policy makers
and commissioners.
In designing The LASER Trial, we have attempted to
maintain a pragmatic approach to ensure as wide as
possible external applicability of the results. We have
had engagement from our PPI members at all stages of
trial development from grant application through to trial
design and delivery.
PPI members highlighted the importance of exacerba-
tion frequency as our primary outcome measure as they
are so important to patients with severe asthma, proving
a constant threat to their ability to lead a normal life.
PPI members guided the decision to collect diary data
and peak flow recordings for 2 weeks prior to each fol-
low up visit rather than throughout the 12-month treat-
ment period in an attempt to reduce the burden on trial
participants.
PPI members have also been integral in the design of the
trial paperwork (participant information sheet, consent
forms and diaries) and trial website. PPI review ensured
that the information delivered was applicable to patients
and that the plain English summaries were accessible to all.
PPI members were present at each of our patient
information events, held to enhance recruitment to the
trial. Patient representatives supported the trial team in
delivering the presentation and fielding questions about
the trial.
The eligibility criteria chosen for the trial were
intended to be as inclusive as possible whilst reflecting
normal clinical practice and ensuring internal validity
and appropriate scientific rigor. The most current
international respiratory society guidance was used for
the definition of severe asthma and in defining severe
exacerbations. Well-validated questionnaire tools and
patient-reported outcome tools were chosen to monitor
clinical outcomes.
Trial status
The LASER Trial is now open to recruitment with 14
sites across England currently recruiting participants
to the trial. Further information about the trial
including updates on trial progress can be found at
www.lasertrial.co.uk.
Abbreviations
ACQ: Asthma Control Questionnaire; ACQoL: Adult Carer Quality of Life
questionnaire; ANCOVA: Analysis of Covariance; AQLQ: Asthma Quality of Life
Questionnaire; ATS: American Thoracic Society; BMI: Body Mass Index;
COPD: Chronic Obstructive Pulmonary Disease; CPAP: Continuous Positive
Airway Pressure; CRF: Case Report Form; DSMC: Data Safety and Monitoring
Committee; EQ-5D-5L: EuroQol 5-Dimension 5-Level Questionnaire;
ERS: European Respiratory Society; GCP: Good Clinical Practice; GETE: Global
Evaluation of Treatment Effect; HTA: Health Technology Assessment;
IgE: Immunoglobulin E; ITT: Intention To Treat; NHS: National Health Service;
NIV: Non-Invasive Ventilation; ORTU: Oxford Respiratory Trials Unit; PEF: Peak
Expiratory Flow; PI: Principal Investigator; PPI: Patient and Public Involvement;
QALY: Quality Adjusted Life Year; SNOT-22: Sino-Nasal Outcome Test - 22
items; SPT: Skin Prick Testing; TLA: Temperature-controlled Laminar Airflow;
TMG: Trial Management Group; TSC: Trial Steering Committee; WPAI-A: Work
Productivity Activity Impairment questionnaire - Asthma; WPAI-CG: Work
Productivity Activity Impairment questionnaire – Care Giver.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
WS, CF and TB have made substantial contributions to the conception and
design of the trial and drafting of the manuscript. PH, PB, AM, PD, LMY, AD,
TD and NR have made substantial contributions to the conception, design
and delivery of the trial. RLF has made substantial contributions to the
conception and trial design regarding healthcare utilisation. AJC has made
substantial contributions to the conception and design, manuscript revision,
and final approval of the manuscript and is chief investigator of the trial.
All authors have approved the final version of the manuscript.
Acknowledgements
We would especially like to thank our patient representatives, Mrs. Sandra
Willsher, Mr. Keith Boughton and Mr. Keith Manship for their contributions to
the development of the trial, including the study design and outcome
measures, and for providing their ongoing enthusiastic support. We would
also like to thank Asthma UK and Allergy UK for supporting the trial.
The images used in Fig. 2 are reproduced with the consent of the device
manufacturer Airsonett.
Funding statement
The LASER Trial is funded by the National Institute for Health Research
Health Technology Assessment Programme (Project Number 12/33/28).
Author details
1Portsmouth Hospitals NHS Trust, Portsmouth, UK. 2University Hospital
Southampton NHS Foundation Trust, Southampton, UK. 3Centre for Statistics
in Medicine, Oxford University, Oxford, UK. 4University of Portsmouth,
Portsmouth, UK. 5Health Economics Research Unit, Nuffield Department of
Population Health, University of Oxford, Oxford, UK. 6Oxford Respiratory Trials
Unit, University of Oxford, Oxford, UK. 7Heart of England NHS Foundation
Trust, Birmingham, UK. 8University Hospitals of Leicester NHS Trust, Leicester,
UK.
Received: 17 June 2015 Accepted: 18 December 2015
References
1. Asthma UK. Living on a Knife Edge. A powerful and moving account of
living with serious symptoms of asthma. London: Asthma UK, 2004.
2. Holgate ST, Polosa R. The mechanisms, diagnosis and management of
severe asthma in adults. Lancet. 2006;368:780–93.
3. Hoskins G, McCowan C, Neville RG, Thomas GE, Smith B, Silverman S.
Risk factors and costs associated with an asthma attack’. Thorax.
2000;55:19–24.
4. Manson SC, Brown RE, Cerulli A, Vidaurre CF. The cumulative burden of oral
corticosteroid side effects and the economic implications of steroid use.
Respir Med. 2009;103:975–94.
5. Humbert M, Beasley R, Ayres J, Slavin R, Hébert J, Bousquet J, et al.
Benefits of Omalizumab as add-on therapy in patients with severe persistent
Storrar et al. Trials  (2016) 17:15 Page 12 of 13
asthma who are inadequately controlled despite best available therapy (GINA
2002 step 4 treatment): INNOVATE. Allergy. 2005;60:309–16.
6. National Institute for Health and Care Excellence. Omalizumab for treating severe
persistent allergic asthma (review of technology appraisal guidance 133 and 201)
[Internet] London, England: NICE; Apr, 2013. (NICE technology appraisal guidance
278). Available from: https://www.nice.org.uk/guidance/ta278.
7. British Thoracic Society/Scottish Intercollegiate Guidelines Network. British
guideline on the management of asthma. Thorax. 2014;69 (Suppl 1): 1-192.
8. Bousquet J, Mantzouranis E, Cruz AA, Aït-Khaled N, Baena-Cagnani CE,
Bleecker ER, et al. Uniform definition of asthma severity, control and
exacerbations: document presented for the World Health Organisation
consultation on Severe Asthma. J Allergy Clin Immunol. 2010;126:926–38.
9. Heaney LG, Brightling CE, Menzies-Gow A, Stevenson M, Niven RM, British
Thoracic Society Difficult Asthma Network. Refractory asthma in the UK:
cross-sectional findings from a UK multicentre registry. Thorax. 2010;65:787–94.
10. Custovic A, Taggart SC, Francis HC, Chapman MD, Woodcock A. Exposure to
house dust mite allergens and the clinical activity of asthma. J Allergy Clin
Immunol. 1996;98:64–72.
11. Tunnicliffe WS, Fletcher TJ, Hammond K, Roberts K, Custovic A, Simpson A,
et al. Sensitivity and exposure to indoor allergens in adults with differing
asthma severity. Eur Respir J. 1999;13:654–9.
12. Langley SJ, Goldthorpe S, Craven M, Morris J, Woodcock A, Custovic A.
Exposure and sensitisation to indoor allergens: Association with lung
function, bronchial reactivity and exhaled nitric oxide measures in asthma.
J Allergy Clin Immunol. 2003;112:362–8.
13. Rosenstreich DL, Eggleston P, Kattan M, Baker D, Slavin RG, Gergen P, et al.
The role of cockroach allergy and exposure to cockroach allergen in causing
morbidity among inner-city children with asthma. NEJM. 1997;336:1356–63.
14. Custovic A, Simpson A, Chapman MD, Woodcock A. Allergen avoidance in
the treatment of asthma and atopic disorders. Thorax. 1998;53:63–72.
15. Van Velzen E, van den Bos JW, Benckhuijsen JA, van Essel T, de Bruijn R,
Aalbers R. Effect of allergen avoidance at high altitude on direct and
indirect bronchial hyperresponsiveness and markers of inflammation
inchildren with allergic asthma. Thorax. 1996;51:582–4.
16. Peroni DG, Boner AL, Vallone G, Antolini I, Warner JO. Effective allergen
avoidance at high altitude reduces allergen-induced hyperresponsiveness.
Am J Respir Crit Care Med. 1994;149:1442–6.
17. Grootendorst DC, Dahlén SE, Van Den Bos JW, Duiverman EJ,
Veselic-Charvat M, Vrijlandt EJ, et al. Benefits of high altitude allergen avoidance
in atopic adolescents with moderate to severe asthma over and above treatment
with high dose inhaled steroids. Clin Exp Allergy. 2001;31:400–8.
18. Gøtzsche PC, Johansen HK. House dust mite control measures for asthma.
Cochrane Database of Systematic Reviews. 2008, Issue 2. Art. No.: CD001187.
DOI:10.1002/14651858.CD001187.pub3.
19. Sublett JL. Effectiveness of air filters and air cleaners in allergic respiratory
diseases: a review of the recent literature. Curr Allergy Asthma Rep.
2011;11:395–402.
20. Sigsgaard T. Temperature regulated Laminair Airflow (TLA): TLA principles
and practise, presented at European Academy of Allergy and Clinical
Immunology 2010 Congress, London
21. Gore RB, Boyle RJ, Hanna H, Custovic A, Gore C, Svensson P, et al. Personal
allergen exposures are increased by changes in sleep position and improved by
temperature controlled laminar airflow. Thorax. 2010;65:A87–8.
22. Sigsgaard T, Ravn P, Svensson P, Takai H. A comparison of the effectiveness
of a temperature controlled laminar airflow device and a room air-cleaner
in reducing particle concentrations in the breathing zone of a thermal
manikin lying in a bed. 2010. Allergy. 65(Suppl. 92):694–756
23. Boyle RJ, Pedroletti C, Wickman M, Bjermer L, Valovirta E, Dahl R, et al.
Nocturnal Temperature Controlled Laminar Airflow for Treating Atopic
Asthma: a randomised controlled trial. Thorax. 2012;65:215–21.
24. Chung KF, Wenzel SE, Brozek JL, Bush A, Castro M, Sterk PJ, et al.
International ERS/ATS guidelines on definition, evaluation and treatment of
severe asthma. Eur Respir J. 2013. doi:10.1183/09031936.00202013.
25. Reddel HK, Taylor DR, Bateman ED, Boulet LP, Boushey HA, Busse WW, et al.
An Official American Thoracic Society/European Respiratory Society Statement:
Asthma Control and Exacerbations. Standardizing Endpoints for Clinical Asthma
Trials and Clinical Practice. Am J Respir Crit Care Med. 2009;180:59–99.
26. Brooks R, Rabin R, Charro F. The measurement and valuation of health
status using EQ-5D: a European perspective: evidence from the EuroQol BIO
MED research programme. Rotterdam, The Netherlands: Kluwer Academic
Publishers, Springer; 2003.
27. Curtis L. Unit costs of health and social care 2013. Canterbury: Personal
Social Services Research Unit; 2012.
28. International Conference on Harmonisation of technical requirements for
registration of pharmaceuticals for human use. ICH harmonised tripartite
guideline. Guideline for Good Clinical Practice. Ottawa, Canada: Health
Canada. 1996.
29. Briggs A, Gray A. The distribution of healthcare costs and their statistical
analysis for economic evaluation. J Health Serv Res Policy. 1998;3:233–45.
30. Claxton K, Sculpher M, McCabe C, Briggs A, Akehurst R. Probabilistic
sensitivity analysis for NICE technology assessment: not an optional extra.
Health Econ. 2005;14:339–47.
31. WMA Declaration of Helsinki - Ethical Principles for Medical Research
Involving Human Subjects. 64th WMA General Assembly, Fortaleza, Brazil.
World Medical Journal. 2013;59 (5):199.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Storrar et al. Trials  (2016) 17:15 Page 13 of 13
